| Heather Mironas, | |
|
5460 E La Palma Ave, Anaheim, CA 92807-2023 | |
| (714) 449-7401 | |
| Not Available |
| Full Name | Heather Mironas |
|---|---|
| Gender | Female |
| Speciality | Optometry |
| Experience | 8 Years |
| Location | 5460 E La Palma Ave, Anaheim, California |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1467804914 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | OPT 33502 (California) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Monument Vision Clinic Pc | 8628241668 | 4 |
News Archive
Neovasc Inc., a developer of novel technologies used to treat vascular disease, today presented results from the follow-up phase of the initial clinical trial of its Neovasc Reducer(TM) product at the American College of Cardiology 2010 annual meeting. The Neovasc Reducer is a novel implantable product designed to treat heart disease patients who suffer from refractory angina. The new data shows that three years after implantation of the Reducer, the majority of patients continued to show measurable improvement in angina symptoms.
Genzyme Corporation reported today that four-year follow-up data from its completed Phase 2 multiple sclerosis (MS) trial continued to show durable reductions in relapse rate and sustained accumulation of disability three years after the majority of patients received their last course of the investigational compound alemtuzumab.
Invida Group, the leading specialty biopharmaceutical company focused on the commercialization of healthcare products throughout Asia Pacific, today announced that it has completed a joint venture agreement with the Indonesian pharmaceutical manufacturer MUGI.
Teen girls-but not boys-who prefer to go to bed later are more likely to gain weight, compared to same-age girls who go to bed earlier, suggests a study funded by the National Institutes of Health.
Pharmacyclics, Inc announced today updated results from three trials of Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), for the treatment of patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
› Verified 9 days ago
| Provider Name | Monument Vision Clinic Pc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1588967228 PECOS PAC ID: 8628241668 Enrollment ID: O20111107000822 |
News Archive
Neovasc Inc., a developer of novel technologies used to treat vascular disease, today presented results from the follow-up phase of the initial clinical trial of its Neovasc Reducer(TM) product at the American College of Cardiology 2010 annual meeting. The Neovasc Reducer is a novel implantable product designed to treat heart disease patients who suffer from refractory angina. The new data shows that three years after implantation of the Reducer, the majority of patients continued to show measurable improvement in angina symptoms.
Genzyme Corporation reported today that four-year follow-up data from its completed Phase 2 multiple sclerosis (MS) trial continued to show durable reductions in relapse rate and sustained accumulation of disability three years after the majority of patients received their last course of the investigational compound alemtuzumab.
Invida Group, the leading specialty biopharmaceutical company focused on the commercialization of healthcare products throughout Asia Pacific, today announced that it has completed a joint venture agreement with the Indonesian pharmaceutical manufacturer MUGI.
Teen girls-but not boys-who prefer to go to bed later are more likely to gain weight, compared to same-age girls who go to bed earlier, suggests a study funded by the National Institutes of Health.
Pharmacyclics, Inc announced today updated results from three trials of Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), for the treatment of patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Heather Mironas, 5460 E La Palma Ave, Anaheim, CA 92807-2023 Ph: (714) 449-7401 | Heather Mironas, 5460 E La Palma Ave, Anaheim, CA 92807-2023 Ph: (714) 449-7401 |
News Archive
Neovasc Inc., a developer of novel technologies used to treat vascular disease, today presented results from the follow-up phase of the initial clinical trial of its Neovasc Reducer(TM) product at the American College of Cardiology 2010 annual meeting. The Neovasc Reducer is a novel implantable product designed to treat heart disease patients who suffer from refractory angina. The new data shows that three years after implantation of the Reducer, the majority of patients continued to show measurable improvement in angina symptoms.
Genzyme Corporation reported today that four-year follow-up data from its completed Phase 2 multiple sclerosis (MS) trial continued to show durable reductions in relapse rate and sustained accumulation of disability three years after the majority of patients received their last course of the investigational compound alemtuzumab.
Invida Group, the leading specialty biopharmaceutical company focused on the commercialization of healthcare products throughout Asia Pacific, today announced that it has completed a joint venture agreement with the Indonesian pharmaceutical manufacturer MUGI.
Teen girls-but not boys-who prefer to go to bed later are more likely to gain weight, compared to same-age girls who go to bed earlier, suggests a study funded by the National Institutes of Health.
Pharmacyclics, Inc announced today updated results from three trials of Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), for the treatment of patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
› Verified 9 days ago
Tina Do Optometry, Inc. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 440 N Euclid St, Anaheim, CA 92801 Phone: 714-956-2785 | |
Dr. Derek Kwon Optometry, Inc Optometrist Medicare: Medicare Enrolled Practice Location: 731 N Euclid St, Anaheim, CA 92801 Phone: 714-533-8240 | |
Krupa J Patel, OD Optometrist Medicare: Medicare Enrolled Practice Location: 5460 E La Palma Ave, Anaheim, CA 92807 Phone: 714-463-7569 | |
Dr. Garrett Scott Wada, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 936 S Brookhurst St, Anaheim, CA 92804 Phone: 714-533-2525 Fax: 714-242-9564 | |
Ely R Almaleh, OD Optometrist Medicare: Not Enrolled in Medicare Practice Location: 441 N Lakeview Ave, Anaheim, CA 92807 Phone: 888-988-2800 | |
Steven Hoffman, Optometrist Medicare: Medicare Enrolled Practice Location: 5460 E La Palma Ave, Anaheim, CA 92807 Phone: 714-463-7500 Fax: 714-992-7850 | |
Ms. Teresa Xuan Do, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 500 S Euclid St Ste D, Anaheim, CA 92802 Phone: 714-635-1100 Fax: 714-635-1155 |